A dual-action niclosamide-based prodrug that targets cancer stem cells and inhibits TNBC metastasis.
Kim JH, Park S, Jung E, Shin J, Kim YJ, Kim JY, Sessler JL, Seo JH, Kim JS.
Kim JH, et al.
Proc Natl Acad Sci U S A. 2023 May 23;120(21):e2304081120. doi: 10.1073/pnas.2304081120. Epub 2023 May 15.
Proc Natl Acad Sci U S A. 2023.
PMID: 37186828
Free PMC article.
Here, we report a prodrug, Nic-A, created by combining a carbonic anhydrase IX (CAIX) inhibitor, acetazolamide, with a signal transducer and transcriptional activator 3 (STAT3) inhibitor, niclosamide. Nic-A was designed to target triple-negative breast cancer (TNBC) …
Here, we report a prodrug, Nic-A, created by combining a carbonic anhydrase IX (CAIX) inhibitor, acetazolamide, with a signal transducer and …